Pancreatic Cancer Research

ResearcherZhengzhou UniversityActive in the last 2 years

Xinfang Hou

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5112905453. Sources: OpenAlex.

Their work

Papers
3
Trials
0
Grants
0
Labs led
0
Collaborators
9
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 3

  1. Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer. Co-author DOI 10.1038/s41416-025-03286-w↗
  2. Anoctamin 5 regulates cell proliferation and migration in pancreatic cancer. Co-author PMID 31933826↗
  3. Effects of obatoclax combined with gemcitabine on the biological activity of pancreatic cancer cells under hypoxic conditions. Co-author DOI 10.3892/mmr.2018.8932↗

Closest collaborators

The 9 strongest of 9 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jianzhen Shan · 1 shared paper, 2026 · strength 0.24
  2. Noboru Yamamoto · 1 shared paper, 2026 · strength 0.24
  3. Dong Yan · 1 shared paper, 2026 · strength 0.24
  4. Vinod Ganju · 1 shared paper, 2026 · strength 0.24
  5. Rui‐Hua Xu · 1 shared paper, 2026 · strength 0.24
  6. Haiyan Song · 1 shared paper, 2019 · strength 0.14
  7. Hui Lian · 1 shared paper, 2019 · strength 0.14
  8. Ju‐Feng Wang · 1 shared paper, 2018 · strength 0.10
  9. Ke Li · 1 shared paper, 2018 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.